Scarica l'app Stockscreener
6.59
0.90%
-0.06
Dopo l'orario di chiusura:
6.59
Precedente Chiudi:
$6.65
Aprire:
$6.65
Volume 24 ore:
397.51K
Relative Volume:
1.03
Capitalizzazione di mercato:
$159.21M
Reddito:
$68.38M
Utile/perdita netta:
$-20.17M
Rapporto P/E:
-7.4556
EPS:
-0.8839
Flusso di cassa netto:
$-14.13M
1 W Prestazione:
+41.11%
1M Prestazione:
+49.77%
6M Prestazione:
+87.75%
1 anno Prestazione:
-26.04%
Intervallo 1D:
$6.46
$6.76
Intervallo di 1 settimana:
$4.3801
$7.10
Portata 52W:
$2.59
$12.23
Exagen Inc Stock (XGN) Company Profile
Nome
Exagen Inc
Settore
Industria
Telefono
(760) 560-1501
Indirizzo
1261 LIBERTY WAY, VISTA, CA
Compare XGN vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
6.59 | 106.30M | 68.38M | -20.17M | -14.13M | -0.8839 |
TMO
Thermo Fisher Scientific Inc
|
580.02 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
199.98 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
590.00 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
141.34 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
399.70 | 36.45B | 3.77B | 449.25M | 240.68M | 7.8556 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-11 | Iniziato | B. Riley Securities | Buy |
| 2025-07-30 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-07-23 | Iniziato | Craig Hallum | Buy |
| 2022-08-05 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-04-15 | Iniziato | Canaccord Genuity | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-10-08 | Iniziato | BTIG Research | Buy |
| 2020-06-02 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-10-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-10-14 | Iniziato | Cowen | Outperform |
| 2019-10-14 | Iniziato | William Blair | Outperform |
Mostra tutto
Exagen Inc Borsa (XGN) Ultime notizie
Exagen Inc. to Participate in Upcoming Investor Conference - The Manila Times
Exagen Inc (XGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Exagen Inc (XGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
XGN|Exagen Inc|Price:4.390|Chg%:-0.290 - TradingKey
Exagen Inc (XGN) Institutional Confidence - TradingKey
Exagen Inc (XGN) Balance Sheet - TradingKey
Exagen Inc (XGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Exagen Inc (XGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Exagen Inc (XGN) Income Statement - TradingKey
TradingKey - TradingKey
XGN|Exagen Inc|Price:4.680|Chg%:-0.270 - TradingKey
Exagen Inc (XGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Exagen Inc (XGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Exagen nears break-even with strong revenue gro... - Pluang
Exagen: A Small Diagnostics Company Approaching An Inflection Point (NASDAQ:XGN) - Seeking Alpha
Exagen stock stabilizes as autoimmune testing revenue grows and losses narrow - Ad-hoc-news.de
New Exagen study finds variability in myositis antibody detection methods - Traders Union
Exagen schedules 8:30 a.m. call to review second-quarter results - Stock Titan
ETFs Investing in Exagen, Inc. Stocks - TradingView
Exagen (XGN) Q1 2026 Earnings: EPS Beat Fails to Lift Stock, Revenue Concerns LingerTech Earnings Analysis - dars.gov.et
Exagen Inc. (XGN) Q1 2026 Earnings: Narrower Loss Beats Street Estimates, Yet Shares DeclineFinal Results - dars.gov.et
Exagen Inc focuses on autoimmune diagnostics as investors watch strategy - Ad Hoc News
Exagen Company Profile & Introduction - Moomoo
Exagen Inc. (XGN) Faces Selling Pressure, Testing Key Support at $4.31MFI Divergence - dars.gov.et
XGNExagen Inc Volatility & Greeks - Finviz
Exagen Inc. (XGN) Edges Higher as Stock Consolidates Near Key Support LevelNAAIM Leverage - dars.gov.et
Price to earnings forward of Exagen, Inc. – LS:A2PRXT - TradingView
Enterprise value to EBIT forward of Exagen Inc. – NASDAQ:XGN - TradingView
A2PRXT Forecast — Price Target — Prediction for 2027 - TradingView
Exagen Inc. (XGN) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Stock ResponseSpecial Dividend Alert - dars.gov.et
Price to book forward of Exagen Inc. – NASDAQ:XGN - TradingView
Enterprise value to EBIT forward of Exagen, Inc. – GETTEX:E08A - TradingView
Enterprise value to EBITDA forward of Exagen Inc. – NASDAQ:XGN - TradingView
Price to sales forward of Exagen Inc. – NASDAQ:XGN - TradingView
Price to sales forward of Exagen, Inc. – GETTEX:E08A - TradingView
Enterprise value to revenue forward of Exagen Inc. – NASDAQ:XGN - TradingView
Enterprise value to revenue forward of Exagen Inc. – BOATS:XGN - TradingView
Exagen, Inc. Actuals & Estimates (NASDAQ:XGN) - TradingView
Exagen sets dates for second-quarter results, shares watched around Nasdaq listing - ad-hoc-news.de
E08A Forecast — Price Target — Prediction for 2027 - TradingView
XGN Forecast — Price Target — Prediction for 2027 - TradingView
XGN Initiates Coverage On Exagen -- Roth Capital Assigns Buy Rat - GuruFocus
XGN Q1 2026 Earnings: EPS Beat Drives Positive Stock MovementStrong Earnings Momentum - dars.gov.et
Exagen (XGN) Gains Buy Rating with $8 Price Target from Analyst - GuruFocus
Form 4 Exagen Inc For: 24 June By Investing.com - Investing.com Nigeria
Form 4 Exagen Inc For: 22 June By Investing.com - Investing.com Australia
Exagen (XGN) director Scott Kahn receives 37,500 stock options grant - Stock Titan
Exagen (XGN) director granted 37,500 stock options at $4.31 strike - Stock Titan
Exagen (XGN) director Frank Stokes receives 37,500 stock options at $4.31 - Stock Titan
Form 4 Exagen Inc For: 22 June - Investing.com India
Exagen StockSunday background on autoimmune diagnostics specialist - AD HOC NEWS
Exagen Inc Azioni (XGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Exagen Inc Azioni (XGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ABALLI JOHN | President and CEO |
Feb 24 '26 |
Sale |
3.61 |
11,430 |
41,262 |
702,997 |
| Black Jeffrey G. | Chief Financial Officer |
Feb 24 '26 |
Sale |
3.61 |
1,584 |
5,718 |
267,442 |
| ABALLI JOHN | President and CEO |
Oct 16 '25 |
Sale |
11.82 |
31,787 |
375,598 |
714,427 |
| Black Jeffrey G. | Chief Financial Officer |
Sep 02 '25 |
Sale |
9.79 |
20,466 |
200,362 |
269,026 |
1.13%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):